Ticker Details
MannKind Corporation MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.
IPO Date:	July 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.7B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 3.00%
Avg Daily Range (30 D):	$0.15 | 2.58%
Avg Daily Range (90 D):	$0.11 | 2.02%

Institutional Daily Volume
Avg Daily Volume:	1.7M
Avg Daily Volume (30 D):	2.9M
Avg Daily Volume (90 D):	3M

Trade Size
Avg Trade Size (Sh.):	184
Avg Trade Size (Sh.) (30 D):	165
Avg Trade Size (Sh.) (90 D):	166

Institutional Trades
Total Institutional Trades:	3,848
Avg Institutional Trade:	$1.57M
Avg Institutional Trade (30 D):	$2.11M
Avg Institutional Trade (90 D):	$2.44M
Avg Institutional Trade Volume:	.24M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.88M
Avg Closing Trade (30 D):	$2.41M
Avg Closing Trade (90 D):	$2.93M
Avg Closing Volume:	368.19K

News

Feb 19, 2026 @ 2:00 PM MannKind to Participate in the Oppenheimer 36th An... Source: Na

Jan 29, 2026 @ 6:31 PM Longevity Biotech Stocks Surge as $27 Trillion Hea... Source: Prnewswire

Jan 23, 2026 @ 5:56 PM Breaking Barriers: How 2026’s Top Clinical ... Source: Equity Insider

Jan 8, 2026 @ 1:05 PM MannKind Provides Business Updates and 2026 Growth... Source: Globe Newswire

Dec 24, 2025 @ 11:16 PM Is MannKind Stock a Buy or Sell After the CEO Sold... Source: Robert Izquierdo

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$.1	$.03	$
Diluted EPS	$.1	$.03	$
Revenue	$313.79M	$82.13M	$76.53M
Gross Profit	$296.11M	$77.63M	$71.92M
Net Income / Loss	$29.23M	$7.99M	$.67M
Operating Income / Loss	$72.98M	$18.9M	$5.3M
Cost of Revenue	$17.68M	$4.5M	$4.61M
Net Cash Flow	$65.03M	$70.39M	$9.7M
PE Ratio	56.00

Splits
Mar 03, 2017	1:5